These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9987152)

  • 1. Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine.
    Herlocher ML; Ewasyshyn M; Sambhara S; Gharaee-Kermani M; Cho D; Lai J; Klein M; Maassab HF
    Vaccine; 1999 Jan; 17(2):172-81. PubMed ID: 9987152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.
    Crowe JE; Firestone CY; Murphy BR
    J Immunol; 2001 Oct; 167(7):3910-8. PubMed ID: 11564809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.
    Karron RA; Wright PF; Crowe JE; Clements-Mann ML; Thompson J; Makhene M; Casey R; Murphy BR
    J Infect Dis; 1997 Dec; 176(6):1428-36. PubMed ID: 9395351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine pattern is solely influenced by priming vaccine but immunity and disease by both priming and boosting vaccines in mice challenged with respiratory syncytial virus.
    Tang YW
    Virus Res; 2004 Jan; 99(1):81-7. PubMed ID: 14687950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes.
    Meng J; Lee S; Hotard AL; Moore ML
    mBio; 2014 Sep; 5(5):e01704-14. PubMed ID: 25249281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.
    Crowe JE; Bui PT; London WT; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1994 Jun; 12(8):691-9. PubMed ID: 8091846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.
    Crowe JE; Bui PT; Davis AR; Chanock RM; Murphy BR
    Vaccine; 1994 Jul; 12(9):783-90. PubMed ID: 7975856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.
    Russell RF; McDonald JU; Ivanova M; Zhong Z; Bukreyev A; Tregoning JS
    J Virol; 2015 Sep; 89(17):8974-81. PubMed ID: 26085154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus.
    Hsu KH; Crowe JE; Lubeck MD; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1995 Apr; 13(5):509-15. PubMed ID: 7543716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.
    Crowe JE; Bui PT; Firestone CY; Connors M; Elkins WR; Chanock RM; Murphy BR
    J Infect Dis; 1996 Apr; 173(4):829-39. PubMed ID: 8603960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo.
    Crowe JE; Randolph V; Murphy BR
    Virus Res; 1999 Jan; 59(1):13-22. PubMed ID: 10854162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.
    Crowe JE; Bui PT; Siber GR; Elkins WR; Chanock RM; Murphy BR
    Vaccine; 1995 Jun; 13(9):847-55. PubMed ID: 7483808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.